Alzheimer’s & Dementia | December 22, 2023

Xiao Z, Wu W, Ma X, Wu J, Liang X, Zhou X, Cao Y, Zhao Q, Ding D.

Alzheimers Dement (Amst). 2023

https://doi.org/10.1002/dad2.12514

Abstract

INTRODUCTION

Blood biomarkers showed values for predicting future cognitive impairment. Evidence from the community-based cohort was limited only in high-income countries.

METHODS

This study included 1857 dementia-free community residents recruited in 2009–2011 and followed up in waves 2014–2016 and 2019–2023 in the Shanghai Aging Study. We intended to explore the relationships of baseline plasma ALZpath phosphorylated tau 217 (p-tau217), p-tau181, neurofilament light chain (NfL) with follow-up incident dementia, Alzheimer’s disease (AD), and amyloidosis.

RESULTS

Higher concentrations of plasma p-tau217, p-tau181, and NfL were correlated to higher decline speed of Mini-Mental State Examination score, and higher risk of incident dementia and AD. The p-tau217 demonstrated a significant correlation with longitudinal neocortical amyloid-beta (Aβ) deposition (r = 0.57 [0.30, 0.76]) and a high accuracy differentiating Aβ+ from Aβ- at follow-ups (area under the receiver operating characteristic curve = 0.821 [0.703, 0.940]).

DISCUSSION

Plasma p-tau217 may be an early predictive marker of AD and Aβ pathology in older community-dwelling individuals.